Clinical implications of the differences between diagnostic i and post-therapy i scans

Nuclear Medicine Communications

Volumn 25, Issue 2, 2004, Pages 129-134

  Cohen, Jason B ^a   Kalinyak, Judith E ^a   Ross McDougall, I ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Radioiodine; Staging; Stunning; Thyroid cancer

Indexed keywords

IODINE 123; IODINE 131;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFERENTIATION; DRUG UPTAKE; FEMALE; HUMAN; IODINE 131 UPTAKE TEST; LOW ENERGY RADIATION; MALE; QUALITATIVE DIAGNOSIS; RADIATION DOSE; SCHOOL CHILD; SCINTISCANNING; STAGING; THYROID CANCER;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; THYROID GLAND; THYROID NEOPLASMS; THYROTROPIN;

EID: 1542314888     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200402000-00006     Document Type: Article

References (22)

1. Leger FA, Izembart M, Dagousset F, Barritault L, Baillet G, Chevalier A, Clerc J. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med 1998; 25:242-246.
2. McMenemin RM, Hilditch TE, Dempsey MF, Reed NS. Thyroid stunning after (131)I diagnostic whole-body scanning. J Nucl Med 2001; 42:986-987.
3. Muratet JP, Daver A, Minier JF, Larra F. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med 1998; 39:1546-1550.
4. Park HM, Park YH, Zhou XH. Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma. Thyroid 1997; 7:277-280.
5. Park HM, Perkins OW, Edmondson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 1994; 4:49-54.
6. Kalinyak JE, McDougall IR. Whole-body scanning with radionuclides of iodine and the controversy of thyroid stunning. Nucl Med Commun 2004; 25:(in press).
7. 131I. J Nucl Med 2000; 41:1198-1202.
8. Fatourechi V, Hay ID, Mullan BP, Wiseman GA, Eghbali-Fatourechi GZ, Thorson LM, Gorman CA. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid 2000; 10:573-577.
9. 131I does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun 1997; 18:505-512.
10. Morris LF, Waxman AD, Braunstein GD. The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals. J Clin Endocrinol Metab 2001; 86:3507-3511.
11. Nemec J, Rohling S, Zamrazil V, Pohunkova D. Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers. J Nucl Med 1979; 20:92-97.
12. Pacini F, Lippi F, Formica N, Elisei R, Anelli S, Ceccarelli C, Pinchera A. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 1987; 28:1888-1891.
13. Spies WG, Wojtowicz CH, Spies SM, Shah AY, Zimmer AM. Value of post-therapy whole-body I-131 imaging in the evaluation of patients with thyroid carcinoma having undergone high-dose I-131 therapy. Clin Nucl Med 1989; 14:793-800.
14. Waxman A, Ramanna L, Chapman N, Chapman D, Brachman M, Tanasescu D, et al. The significance of I-131 scan dose in patients with thyroid cancer: determination of ablation: concise communication. J Nucl Med 1981; 22:861-865.
15. Hilditch TE, Dempsey MF, Bolster AA, McMenemin RN, Reed NS. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic (131)I and (123)I. Eur J Nucl Med Mol Imaging 2002; 29:783-788.
16. Yaakob W, Gordon L, Spicer KM, Nitke SJ. The usefulness of iodine-123 whole-body scans in evaluating thyroid carcinoma and metastases. J Nucl Med Technol 1999; 27:279-281.
17. Gerard SK, Cavalieri RR. I-123 diagnostic thyroid tumor whole-body scanning with imaging at 6, 24, and 48 hours. Clin Nucl Med 2002; 27:1-8.
18. Kalinyak JE. 123 I as a diagnostic tracer in the management of thyroid cancer. Nucl Med Commun 2002; 23:509-511.
19. Gulzar Z, Jana S, Young I, Bukberg P, Yen V, Naddaf S, Abdel-Dayem HM. Neck and whole-body scanning with 5-mCi dose of 123 I as diagnostic tracer in patients with well-differentiated thyroid cancer. Endocr Pract 2001; 7:244-249.
20. Mandel SJ, Shankar LK, Benard F, Yamamoto A, Alavi A. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nucl Med 2001; 26:6-9.
21. 131I for whole-body imaging in thyroid cancer. J Nucl Med 2002; 43:632-634.
22. 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2002; 29:768-774.